|piosys belongs to the class of anti-diabetic drugs called "thiazolidinediones" that are used for the management of type ii diabetes mellitus.|
|mechanism of action||piosys decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Unlike sulfonylureas, pioglitazone is not an insulin secretagogue. |
pioglitazone is a potent agonist for peroxisome proliferator-activated receptor-gamma (pparγ). Ppar receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle, and liver.
activation of pparγ nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism.
|indication||in type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus, niddm)|
|dosage||piosys monotherapy is given in patients not adequately controlled with diet and exercise may be initiated at 15 mg or 30 mg once daily. For patients who respond inadequately to the initial dose of piosys, the dose can be increased in increments up to 45 mg once daily.|
|side effects||edema , weight gain , anemia (1%) , myalgia (3%) , headache, hepatotoxicity (rare), fracture of bone, macular retinal edema|
|sales pack||piosys : pack of 100 tabs/ box (10 x 10)|